Compare DOLE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | EVO |
|---|---|---|
| Founded | 1851 | 1993 |
| Country | Ireland | Germany |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2021 | 2021 |
| Metric | DOLE | EVO |
|---|---|---|
| Price | $15.24 | $3.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 936.7K | 264.3K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $8,974,210,000.00 | $887,396,457.00 |
| Revenue This Year | $9.28 | N/A |
| Revenue Next Year | $1.84 | $8.80 |
| P/E Ratio | $101.35 | ★ N/A |
| Revenue Growth | ★ 7.09 | N/A |
| 52 Week Low | $12.20 | $2.84 |
| 52 Week High | $15.73 | $5.10 |
| Indicator | DOLE | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 42.59 |
| Support Level | $15.32 | $2.87 |
| Resistance Level | $15.65 | $3.05 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 57.32 | 35.14 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.